Department of Pediatric Oncology, Hematology, Immunology, and Pulmology, University Children's Hospital, Im Neuenheimer Feld 430, Heidelberg, Germany.
Strahlenther Onkol. 2012 Feb;188(2):168-76. doi: 10.1007/s00066-011-0028-5. Epub 2012 Jan 18.
Osteosarcoma and atypical teratoid rhabdoid tumors are tumor entities with varying response to common standard therapy protocols. Histone acetylation affects chromatin structure and gene expression which are considered to influence radiation sensitivity. The aim of this study was to investigate the effect of the combination therapy with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) and irradiation on atypical teratoid rhabdoid tumors and osteosarcoma compared to normal tissue cell lines.
Clonogenic assay was used to determine cell survival. DNA double-strand breaks (DSB) were examined by pulsed-field electrophoresis (PFGE) as well as by γH2AX immunostaining involving flow cytometry, fluorescence microscopy, and immunoblot analysis.
SAHA lead to an increased radiosensitivity in tumor but not in normal tissue cell lines. γH2AX expression as an indicator for DSB was significantly increased when SAHA was applied 24 h before irradiation to the sarcoma cell cultures. In contrast, γH2AX expression in the normal tissue cell lines was significantly reduced when irradiation was combined with SAHA. Analysis of initial DNA fragmentation and fragment rejoining by PFGE, however, did not reveal differences in response to the SAHA pretreatment for either cell type.
SAHA increases radiosensitivity in tumor but not normal tissue cell lines. The increased H2AX phosphorylation status of the SAHA-treated tumor cells post irradiation likely reflects its delayed dephosphorylation within the DNA damage signal decay rather than chromatin acetylation-dependent differences in the overall efficacy of DSB induction and rejoining. The results support the hypothesis that combining SAHA with irradiation may provide a promising strategy in the treatment of solid tumors.
骨肉瘤和非典型畸胎样横纹肌样肿瘤是对常见标准治疗方案反应不同的肿瘤实体。组蛋白乙酰化影响染色质结构和基因表达,被认为会影响辐射敏感性。本研究的目的是研究组蛋白去乙酰化酶抑制剂 SAHA 与放疗联合治疗非典型畸胎样横纹肌样肿瘤和骨肉瘤与正常组织细胞系的效果。
采用集落形成实验测定细胞存活。通过脉冲场电泳(PFGE)以及通过 γH2AX 免疫染色结合流式细胞术、荧光显微镜和免疫印迹分析检测 DNA 双链断裂(DSB)。
SAHA 导致肿瘤细胞而非正常组织细胞系的放射敏感性增加。当 SAHA 在照射前 24 小时应用于肉瘤细胞培养物时,γH2AX 表达作为 DSB 的指标显著增加。相比之下,当照射与 SAHA 联合应用时,正常组织细胞系中的 γH2AX 表达显著降低。然而,通过 PFGE 分析初始 DNA 片段化和片段重连,对于任何一种细胞类型,都没有发现对 SAHA 预处理的反应差异。
SAHA 增加肿瘤而非正常组织细胞系的放射敏感性。照射后 SAHA 处理的肿瘤细胞中 H2AX 磷酸化状态的增加可能反映了其在 DNA 损伤信号衰减过程中延迟去磷酸化,而不是与染色质乙酰化依赖性差异相关的 DSB 诱导和重连的整体效果。结果支持了这样一种假设,即联合使用 SAHA 和放疗可能为治疗实体瘤提供一种有前途的策略。